You are here

  • Home
  • Archive
  • Volume 30, Issue 11
  • Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

Article metrics

Article menu
Download PDFPDF
Original research
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

 

Online download statistics by month:

Online download statistics by month: October 2020 to October 2024

AbstractFullPdf
Oct 20203361813
Nov 202039495
Dec 202018375
Jan 20216300
Feb 20216510
Mar 20214201
Apr 20214620
May 20211300
Jun 2021221
Jul 2021431
Aug 2021111
Sep 2021110
Oct 20214800
Nov 20215146
Dec 20213400
Jan 20223200
Feb 20228800
Mar 20227221
Apr 20226411
May 20226510
Jun 20227954
Jul 20225040
Aug 20228532
Sep 20226530
Oct 20227322
Nov 20224300
Dec 20224011
Jan 20232200
Feb 20239700
Mar 20234200
Apr 20232800
May 20232600
Jun 20234202
Jul 20239110
Aug 20235610
Sep 20231600
Oct 20233300
Nov 202310920
Dec 202310933
Jan 20246432
Feb 20244011
Mar 20244675
Apr 20242711
May 20243900
Jun 20249132
Jul 20248010
Aug 20246897
Sep 20244442
Oct 2024200
Total321110669